查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602208

尿道感染市场：按适应症、治疗方法、最终用户分类 - 全球预测 2025-2030

Urinary Tract Infection Market by Clinical Indication (Cystitis, Pyelonephritis, Urethritis), Treatment (Diagnosis, Therapatics), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年尿道感染市场价值为116.7亿美元，预计到2024年将达到124.7亿美元，复合年增长率为6.93%，预计到2030年将达到186.7亿美元。

尿道感染（尿道结石）市场包括与预防和管理泌尿器官系统感染疾病相关的诊断、治疗和设备。解决尿道结石的必要性是因为尿路结石的盛行率很高，尤其是在女性中，频繁復发对医疗保健提出了重大挑战。治疗范围从提供初步诊断服务的初级保健到提供先进治疗解决方案的专科医院。最终使用领域包括私人患者、医疗机构和诊断实验室。影响该市场的主要成长要素包括全球尿道结石负担的增加、诊断技术的进步、医疗保健意识的提高以及针对性抗生素和免疫疗法解决方案的开发。市场正在见证尖端产品开拓带来的机会，例如快速就地检验套件和个人化医疗方法。公司可以透过投资研发来创新快速诊断技术和非抗生素治疗方案来利用这些机会，并可以应对精准医疗日益增长的趋势。

主要市场统计
基准年[2023] 116.7亿美元
预测年份 [2024] 124.7亿美元
预测年份 [2030] 186.7亿美元
复合年增长率（%） 6.93%

然而，由于抗生素抗药性，市场面临限制。抗药性挑战了现有治疗方法的有效性，并促使需要昂贵且耗时的新药开拓。此外，针对创新治疗方法的严格法律规范可能会减缓新解决方案的市场进入速度。为了克服这些障碍，製药和生物技术公司之间的合作加速抗生素创新并探索自然和替代治疗途径可能是可行的解决方案。特别是，这个市场的技术创新已经成熟，包括开拓抗药性抗生素市场、探索益生菌作为预防性解决方案，以及远端监控和管理患者病情的数位医疗应用，都有很大的空间。随着市场的发展，公司必须优先考虑灵活地适应不断变化的消费者行为和监管环境，以在动态的医疗保健环境中保持永续成长和竞争优势。

市场动态：快速发展的尿道感染市场的关键市场洞察

供需的动态交互作用正在改变尿道感染市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 糖尿病和肾结石盛行率增加
    • 女性族群尿道结石发生率高
    • 过度使用抗生素和抗药性增加导致复杂性尿道结石
  • 市场限制因素
    • 尿道感染药物如Aminoglycosides和Azole的副作用
  • 市场机会
    • 加强新型抗生素、疫苗和设备的研究和开发
    • 提高公众意识和医疗保健支出
  • 市场挑战
    • 关于尿道感染的社会耻辱

波特五力：驾驭尿道感染感染市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解尿道感染市场的外部影响

外部宏观环境因素在塑造尿道感染感染市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解尿道感染市场的竞争格局

尿道感染感染市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵尿道感染市场供应商的绩效评估

FPNV 定位矩阵是评估尿道感染市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。四个象限清楚且准确地划分供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析：

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 糖尿病和肾结石盛行率增加
      • 女性族群尿道感染发生率高
      • 过度使用抗生素和抗药性增加导致复杂的尿道感染
    • 抑制因素
      • Aminoglycosides和Azole等治疗药物的副作用
    • 机会
      • 加强新型抗生素、疫苗和设备的研究和开发
      • 公众意识和不断上涨的医疗费用
    • 任务
      • 关于尿道感染的社会耻辱
  • 市场区隔分析
    • 临床适应症：需要强大且先进的药物治疗策略来治疗肾盂肾炎
    • 最终用户：随着远端医疗和电子健康平台的普及，在改进自我管理解决方案方面取得了最新进展
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境
  • 客户客製化

第六章依临床适应症分類的尿道感染市场

  • 膀胱炎
  • 肾盂肾炎
  • 尿道炎

第七章尿道感染治疗市场

  • 诊断
  • 治疗药物
    • Aminoglycosides
    • Azole
    • 奎诺酮
    • β-内酰胺

第八章尿道感染市场：依最终用户分类

  • 医院
  • 自我管理

第九章美洲尿道感染市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太尿道感染市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲尿道感染市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Vivoo 在 CES 2024 上推出家庭数位 UTI 测试
    • NRx Pharmaceuticals 宣布 FDA核准NRX-101 的临床实验(IND) 申请，NRX-101 是一种治疗复杂尿道感染的药物
    • 英恆与美国军方合作开发治疗尿道感染的噬菌体

公司名单

  • Dr. Reddys Laboratories Ltd.
  • Sysmex Corporation
  • AstraZeneca PLC
  • URIT Medical Electronic Co., Ltd.
  • Novartis AG
  • Cipla Limited
  • Pfizer Inc.
  • Bayer AG
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Boehringer Ingelheim International GmbH
  • Shionogi & Co., Ltd.
  • Siemens Healthcare AG
  • AbbVie Inc.
  • F. Hoffmann-La Roche AG
  • Sun Pharmaceutical Industries Limited
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline PLC
  • Teva Pharmaceutical Industries Ltd.
  • Johnson & Johnson Services, Inc.
  • Almirall, SA
  • Eli Lilly and Company
  • Viatris Inc.
  • Merck & Co. Inc.
  • Novo Nordisk A/S
Product Code: MRR-034B50030335

The Urinary Tract Infection Market was valued at USD 11.67 billion in 2023, expected to reach USD 12.47 billion in 2024, and is projected to grow at a CAGR of 6.93%, to USD 18.67 billion by 2030.

The urinary tract infection (UTI) market encompasses diagnostics, therapeutic treatments, and devices related to the prevention and management of infections affecting the urinary system. The necessity of addressing UTIs arises due to their high prevalence, particularly among women, with frequent recurrences posing a significant healthcare challenge. Applications extend from primary care settings offering initial diagnostic services to specialized hospitals providing advanced treatment solutions. End-use sectors include individual patients, healthcare facilities, and diagnostic laboratories. Key growth factors influencing this market are the increasing burden of UTIs globally, advancements in diagnostic technologies, a rise in healthcare awareness, and the development of targeted antibiotics and immunotherapy solutions. The market is witnessing opportunities from cutting-edge product developments such as rapid point-of-care testing kits and personalized medicine approaches. Companies can capitalize on these opportunities by investing in R&D to innovate rapid diagnostic technologies and non-antibiotic therapeutic options, aligning with the growing trend towards precision healthcare.

KEY MARKET STATISTICS
Base Year [2023] USD 11.67 billion
Estimated Year [2024] USD 12.47 billion
Forecast Year [2030] USD 18.67 billion
CAGR (%) 6.93%

However, the market faces limitations due to antibiotic resistance, which challenges the effectiveness of existing treatments and drives the need for new drug development, which can be expensive and time-consuming. Furthermore, stringent regulatory frameworks for innovative therapies may delay market entry of novel solutions. To overcome these barriers, collaboration between pharmaceutical companies and biotech firms for accelerated antibiotic innovation and exploring natural and alternative medicine avenues can be viable solutions. The market presents significant areas for innovation, particularly in the development of resistance-free antibiotics, exploration of probiotics as preventive solutions, and digital healthcare applications for monitoring and managing patient conditions remotely. As the market is evolving, firms need to prioritize agile practices to adapt to shifting consumer behaviors and regulatory landscapes, ensuring sustained growth and maintaining competitive advantage in a dynamic healthcare environment.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Urinary Tract Infection Market

The Urinary Tract Infection Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing Prevalence of Diabetes and Kidney Stones
    • High Incidences of UTI in Female Population
    • Complicated UTI due to Rise in Excessive Use of Antibiotics and Drug-Resistance
  • Market Restraints
    • Adverse Effects of Urinary Tract Infection Treatment Drugs such as Aminoglycosides and Azoles
  • Market Opportunities
    • Rise in R&D for a Novel Class of Antibiotics, Vaccines, and Devices
    • Increase in Awareness among People and Healthcare Expenditure
  • Market Challenges
    • Social Stigma Concerning Urinary Tract Infections

Porter's Five Forces: A Strategic Tool for Navigating the Urinary Tract Infection Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Urinary Tract Infection Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Urinary Tract Infection Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Urinary Tract Infection Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Urinary Tract Infection Market

A detailed market share analysis in the Urinary Tract Infection Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Urinary Tract Infection Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Urinary Tract Infection Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Urinary Tract Infection Market, highlighting leading vendors and their innovative profiles. These include Dr. Reddys Laboratories Ltd., Sysmex Corporation, AstraZeneca PLC, URIT Medical Electronic Co., Ltd., Novartis AG, Cipla Limited, Pfizer Inc., Bayer AG, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Boehringer Ingelheim International GmbH, Shionogi & Co., Ltd., Siemens Healthcare AG, AbbVie Inc., F. Hoffmann-La Roche AG, Sun Pharmaceutical Industries Limited, Bristol-Myers Squibb Company, GlaxoSmithKline PLC, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., Almirall, S.A., Eli Lilly and Company, Viatris Inc., Merck & Co. Inc., and Novo Nordisk A/S.

Market Segmentation & Coverage

This research report categorizes the Urinary Tract Infection Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Clinical Indication, market is studied across Cystitis, Pyelonephritis, and Urethritis.
  • Based on Treatment, market is studied across Diagnosis and Therapatics. The Therapatics is further studied across Aminoglycosides, Azoles, Quinolones, and B-lactam.
  • Based on End User, market is studied across Hospitals and Self-Administered.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing Prevalence of Diabetes and Kidney Stones
      • 5.1.1.2. High Incidences of UTI in Female Population
      • 5.1.1.3. Complicated UTI due to Rise in Excessive Use of Antibiotics and Drug-Resistance
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse Effects of Urinary Tract Infection Treatment Drugs such as Aminoglycosides and Azoles
    • 5.1.3. Opportunities
      • 5.1.3.1. Rise in R&D for a Novel Class of Antibiotics, Vaccines, and Devices
      • 5.1.3.2. Increase in Awareness among People and Healthcare Expenditure
    • 5.1.4. Challenges
      • 5.1.4.1. Social Stigma Concerning Urinary Tract Infections
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Clinical Indication: Need for potent and advanced medication strategies for the management of pyelonephritis
    • 5.2.2. End User: Recent advancements to improve self-administration solutions through the proliferation of telemedicine and e-health platforms
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Urinary Tract Infection Market, by Clinical Indication

  • 6.1. Introduction
  • 6.2. Cystitis
  • 6.3. Pyelonephritis
  • 6.4. Urethritis

7. Urinary Tract Infection Market, by Treatment

  • 7.1. Introduction
  • 7.2. Diagnosis
  • 7.3. Therapatics
    • 7.3.1. Aminoglycosides
    • 7.3.2. Azoles
    • 7.3.3. Quinolones
    • 7.3.4. B-lactam

8. Urinary Tract Infection Market, by End User

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Self-Administered

9. Americas Urinary Tract Infection Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Urinary Tract Infection Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Urinary Tract Infection Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Vivoo launches at-home digital UTI test at CES 2024
    • 12.3.2. NRx Pharmaceuticals Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections
    • 12.3.3. Intron enters collaboration with the US Army on bacteriophages for urinary tract infections

Companies Mentioned

  • 1. Dr. Reddys Laboratories Ltd.
  • 2. Sysmex Corporation
  • 3. AstraZeneca PLC
  • 4. URIT Medical Electronic Co., Ltd.
  • 5. Novartis AG
  • 6. Cipla Limited
  • 7. Pfizer Inc.
  • 8. Bayer AG
  • 9. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 10. Boehringer Ingelheim International GmbH
  • 11. Shionogi & Co., Ltd.
  • 12. Siemens Healthcare AG
  • 13. AbbVie Inc.
  • 14. F. Hoffmann-La Roche AG
  • 15. Sun Pharmaceutical Industries Limited
  • 16. Bristol-Myers Squibb Company
  • 17. GlaxoSmithKline PLC
  • 18. Teva Pharmaceutical Industries Ltd.
  • 19. Johnson & Johnson Services, Inc.
  • 20. Almirall, S.A.
  • 21. Eli Lilly and Company
  • 22. Viatris Inc.
  • 23. Merck & Co. Inc.
  • 24. Novo Nordisk A/S

LIST OF FIGURES

  • FIGURE 1. URINARY TRACT INFECTION MARKET RESEARCH PROCESS
  • FIGURE 2. URINARY TRACT INFECTION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. URINARY TRACT INFECTION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. URINARY TRACT INFECTION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. URINARY TRACT INFECTION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL URINARY TRACT INFECTION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. URINARY TRACT INFECTION MARKET DYNAMICS
  • TABLE 7. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY CYSTITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PYELONEPHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY URETHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AZOLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY QUINOLONES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY B-LACTAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY SELF-ADMINISTERED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM URINARY TRACT INFECTION MARKET SIZE, BY CLINICAL INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM URINARY TRACT INFECTION MARKET SIZE, BY THERAPATICS, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. URINARY TRACT INFECTION MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. URINARY TRACT INFECTION MARKET, FPNV POSITIONING MATRIX, 2023